2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-178214
    CSBP ligand 1 165806-32-6
    CSBP ligand 1 (Compound 36) is a ligand of CSBP, with an IC50 of 0.08 μM for CSBP binding. CSBP ligand 1 can inhibit the production of TNF in mice treated with LPS (HY-D1056). CSBP ligand 1 has no significant inhibitory activity against PGHS-1 (IC50: 16 μM) and 5-LO (IC50: 60 μM). CSBP ligand 1 can be used in the research of inflammation-related diseases.
    CSBP ligand 1
  • HY-178227
    KY19334 2319609-67-9 98%
    KY19334 is a CXXC5-DVL inhibitor. KY19334 can activate the Wnt/β-catenin pathway by inhibiting CXXC5-Dvl interaction. KY19334 can inhibit cancer cells proliferation, migration, invasion and transformation by inhibiting CDK1. KY19334 can accelerate wound healing and exert regenerative effects. KY19334 can be used for the researches of cancer, inflammation, metabolic and neurological disease, such as cutaneous squamous cell carcinoma and diabetes.
    KY19334
  • HY-178230
    EVT‑401 951015-69-3 98%
    EVT‑401 is an anti-inflammatory agent. EVT‑401 can be metabolized and exert pharmacological effects in vivo. EVT‑401 can be used for research on inflammatory conditions.
    EVT‑401
  • HY-178231
    ALK5-IN-85 2766583-86-0
    ALK5-IN-85 (Compound 19) is a TGFβRI (ALK5) inhibitor with an IC50 < 100  nM. ALK5-IN-85 can be used for respiratory diseases including idiopathic pulmonary fibrosis, asthma, COPD and lumg cancer, and dermal and ocular fibrotic conditions research.
    ALK5-IN-85
  • HY-178234
    LY237 1892576-07-6
    LY237 is a highly efficient complete agonist of GPR84 (pEC50 = 10.15). LY237 can be used for research on inflammation and fibrosis conditions.
    LY237
  • HY-178239
    DX-8951 Hydroxy-acid 276680-63-8
    ProAX is a prodrug of phosphoramide. ProAX can effectively increase intracellular ATP levels. ProAX activates the AMPK signaling pathway by increasing the AMP/ATP ratio. ProAX can enhance mitochondrial function and antioxidant capacity while reducing reactive oxygen species (ROS) levels. ProAX has shown significant anti-aging and longevity effects in both human fibroblast and nematode models.
    DX-8951 Hydroxy-acid
  • HY-178240
    rel-(1S,2R)-Dihydro bupropion 102141-11-7
    rel-(1S,2R)-Dihydro bupropion is a metabolite of bupropion. rel-(1S,2R)-Dihydro bupropion can promote endogenous IL-10 production and inhibit Th1 cytokines (IL-12 and TNF-α). rel-(1S,2R)-Dihydro bupropion can induce immune response transition from Th1 to Th2. rel-(1S,2R)-Dihydro bupropion can be used for research on inflammatory conditions.
    rel-(1S,2R)-Dihydro bupropion
  • HY-178259
    α2AR agonist 2 719277-27-7
    α2AR agonist 2 is a selective α2B adrenergic receptor antagonist (IC50 = 1.2 µM). α2AR agonist 2 can be used for research on inflammatory pain and neuropathic pain.
    α2AR agonist 2
  • HY-178270
    PBD derivative-1 2305851-17-4 98%
    PBD derivative-1 (Compound 7-8) is a derivative of PBD, and PBD is the payload in antibody-drug conjugates (ADCs). PBD derivative-1 can be used for the synthesis of ADCs.
    PBD derivative-1
  • HY-178282
    JAK1-IN-19 2169271-17-2
    JAK1-IN-19 (Compound 18) is a potent JAK1 inhibitor with IC50s of 0.02, 0.5, 91 and 0.2 nM against JAK1, JAK2, JAK3 and TYK2. JAK1-IN-19 exhibits improved rat and human intrinsic clearance. JAK1-IN-19 can be used for the studies of atopic dermatitis and other autoimmune diseases.
    JAK1-IN-19
  • HY-178284
    Factor B-IN-7
    Factor B-IN-7 (Compound (I)) is a selective Factor B inhibitor. Factor B-IN-7 inhibits Factor B-C3b interaction to suppress complement hyperactivation. Factor B-IN-7 is promising for research of paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy, and age-related macular degeneration (AMD) associated with complement-mediated diseases.
    Factor B-IN-7
  • HY-178287
    TNF-α-IN-27 340307-20-2 98%
    TNF-α-IN-27 (Compound 1) is a TNF-α inhibitor with inhibition rate of 64% at 10 μM. TNF-α-IN-27 can be used for the researches of inflammation and immunology, such as asthma.
    TNF-α-IN-27
  • HY-178317
    OUL312
    OUL312 is a potent PARP10 inhibitor (IC50 = 20 nM), showing more than 75-fold greater selectivity for PARP15(IC50 = 1500 nM). OUL312 is also at least 18-fold higher than all other human enzymes in the family. OUL312 has a good ADME profile, is able to enter cells, is not toxic, and effectively rescues human cells from PARP10-induced apoptosis at sub-micromolar concentrations. OUL312 can be used for the study of cervical cancer.
    OUL312
  • HY-178320
    LAG-3-IN-2 724757-58-8
    LAG-3-IN-2 (Compound LG-17) is a LAG-3 inhibitor. LAG-3-IN-2 can be used for the study of immunology.
    LAG-3-IN-2
  • HY-178324
    T2M-010 364611-21-2
    T2M-010 is a potent, brain-penetrant TREM2 agonist (Kd = 0.83 μM). T2M-010 activates receptor-proximal signaling, inducing SYK phosphorylation in TREM2-expressing cells, and promotes microglial phagocytosis. T2M-010 can be used for the study of protective microglial responses relevant to Alzheimer’s disease (AD).
    T2M-010
  • HY-178327
    DGKα&ζ-IN-2 3039488-61-1
    DGKα/ζ-IN-2 is a potent, orally active and selective dual DGKα/ζ inhibitor with IC50 values of 23 nM (DGKα) and 1.2 nM (DGKζ). DGKα/ζ-IN-2 exhibits selectivity over other DGK isoforms, such as DGKβ and DGKγ. DGKα/ζ-IN-2 shows robust and dose-dependent immune activation in the presence of antigen presentation in an OT-1 murine model. DGKα/ζ-IN-2 can be used for antitumor immunity.
    DGKα&ζ-IN-2
  • HY-178328
    VDR agonist 4
    VDR agonist 4 is an orally active potent VDR agonist. VDR agonist 4 exerts VDR-dependent antifibrotic activity by regulating multiple fibrosis-related genes to suppress α-SMA and collagen I production, thereby inhibiting hepatic stellate cell (HSC) activation. VDR agonist 4 improves CCl4 (HY-RS16594)-induced hepatic fibrosis in mice. VDR agonist 4 can be used for liver fibrosis research.
    VDR agonist 4
  • HY-178332
    sEH/PPARδ modulator 1
    sEH/PPARδ modulator 1 is a sEH/PPARδ dual modulator. sEH/PPARδ modulator 1 can inhibit sEH with an IC50 of 0.46 μM and activate PPARδ with an EC50 of 0.12 μM. sEH/PPARδ modulator 1 can be used for the researches of inflammation, metabolic and cardiovascular disease.
    sEH/PPARδ modulator 1
  • HY-178336
    AC-340 98%
    AC-340 is a potent hybrid VDR agonist/HDAC inhibitor. AC-340 superinduces VDR target genes (e.g., CYP24A1) and inhibits HDAC6 (IC50 = 0.37 μM) with ~10-fold selectivity over HDAC2. AC-340 induces VDR hyperagonism by causing widespread protein hyperacetylation (e.g., tubulin and H3K9/K27), which leads to elevated H3K27 acetylation on VDR target genes. AC-340 can be used for melanoma cancer research.
    AC-340
  • HY-178342
    Xanthine oxidase-IN-18 98%
    Xanthine oxidase-IN-18 is a potent orally activeXanthine oxidase (XO) inhibitor (IC50 = 0.263 μM). Xanthine oxidase-IN-18 exerts inhibition by directly and stably binding to the xanthine oxidase Mo-co active site. Xanthine oxidase-IN-18 exhibits reactive oxygen species (ROS) scavenging activity. Xanthine oxidase-IN-18 shows anti-hyperuricemia effects in a Potassium oxonate (HY-17511)-induced hyperuricemic rat model. Xanthine oxidase-IN-18 can be used for hyperuricemia, breast and lung cancer research.
    Xanthine oxidase-IN-18
Cat. No. Product Name / Synonyms Application Reactivity